Cabaletta Reports Yearlong Responses in Autoimmune Therapy Trials
PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) reported sustained clinical responses lasting at least one year in small groups of patients with three severe autoimmune diseases following a single …
Cabaletta Reports Yearlong Responses in Autoimmune Therapy Trials Read More